Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2014; 20(40): 14733-14746
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Table 2 Meta-analyses of adjuvant chemotherapy in pancreatic cancer
| Survival (95%CI) | |||||
| Year published | Author | Arm (n) | Median survival (mo) | 2-yr survival | 5-yr survival |
| 2005 | Stocken et al[20] | CT (348) | 19 (16.4-21.1) | 38% | 19% |
| No CT (338) | 13.5 (12.2-15.8) | 28% | 12% | ||
| 2007 | Boeck et al[24] | CT (482) | 3 mo (0.3-5.7) survival benefit | - | 3.1% (-4.6%-10.8%) survival benefit |
| No CT (469) | with CT vs no CT (P = 0.03) | with CT vs no CT (P > 0.05) | |||
| 2008 | Butturini et al[25] | R0 resections | |||
| CT (236) | 20.8 (17.7-23.2) | 42% (35%-48%) | 22% (17%-28%) | ||
| No CT (222) | 13.8 (12.2-16.4) | 27% (21%-33%) | 10% (5%-14%) | ||
| R1 resections | |||||
| CT (109) | 15 (11.7-18.1) | 29% (20%-38%) | 14% (7%-21%) | ||
| No CT (114) | 13.2 (10.5-17.6) | 31% (22%-40%) | 17% (10%-24%) | ||
| 2013 | Liao et al[26] | Hazard ratio for death (95%CI) | |||
| Flurouracil (876) | 0.62 (0.42-0.88) | ||||
| Observation (670) | |||||
| Gemcitabine (774) | 0.68 (0.44-1.07) | ||||
| Observation (670) | |||||
| Gemcitabine (774) | 1.1 (0.70-1.86) | ||||
| Flurouracil (876) | |||||
- Citation: Jones OP, Melling JD, Ghaneh P. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14733-14746
- URL: https://www.wjgnet.com/1007-9327/full/v20/i40/14733.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i40.14733